Cystic fibrosis expert Vertex Pharmaceuticals (NASDAQ: VRTX) reported solid first-quarter earnings after the bell on Thursday and gave an update on its pipeline of next-generation drugs to treat the disease.
Metric
Q1 2017
Cystic fibrosis expert Vertex Pharmaceuticals (NASDAQ: VRTX) reported solid first-quarter earnings after the bell on Thursday and gave an update on its pipeline of next-generation drugs to treat the disease.
Metric
Q1 2017